-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

796 Post-Partum Hemorrhage in Sub-Saharan Africa: A Prospective, Multi-Faceted Intervention Study in Metropolitan Mozambique

Program: Oral and Poster Abstracts
Type: Oral
Session: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases
Hematology Disease Topics & Pathways:
Research, Epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Real-world evidence, Maternal Health
Monday, December 9, 2024: 11:15 AM

Michael Glenzer, MPH1, Momade Correia, MD2*, Virgilio Nhantumbo, MD2*, Daniel Agostinho, MD2*, Elvira Luis, MD2*, Ines Boaventura, MD2*, Sierra Washington, MD3*, Patricia Silva, MD2* and Annette von Drygalski, MD, PharmD, RMSK1

1Center for Bleeding and Clotting Disorders, University of California San Diego, San Diego, CA
2Hospital Central Maputo, Maputo, Mozambique
3Center for Global Health Equity, Stony Brook University, Stony Brook, NY

Introduction: Maternal Mortality (MM) is high in Sub-Saharan Africa (SSA), estimated at ≈500-1,000 maternal deaths per 100,000 live births (vs ≈5-20 in developed countries). Postpartum hemorrhage (PPH) is a known major contributor, but data on contemporary incidence, contribution to mortality and rescue interventions, are scarce.

Aims: To study MM, PPH and the effects of a combined intervention strategy (introduction of cryoprecipitate production capacity in conjunction with an early massive transfusion and standardized PPH care protocol, single-use hemorrhage boxes, PPH education and simulations) prospectively at Maputo Central Hospital (MCH) in Mozambique.

Methods: We collected data on MM, PPH, and associated risk factors prospectively from consecutive deliveries at MCH between February 2019 and January 2021 (pre-intervention), and between October 2022 and April 2024 (post-intervention). Data included age, HIV status, parity, delivery mode, notes, vital signs, laboratory values, and fetal parameters. PPH was determined by charted diagnosis, blood loss >500 mL, the need for transfusion, and/or notes indicating significant bleeding (eg: placental abruption). Patient characteristics and pregnancy outcome data were analyzed descriptively. Group comparisons, including pre- vs post-intervention, were done using Chi-square tests for categorical variables, and T-tests or Mann-Whitney U tests for continuous variables, as appropriate. Models were fit using logistic regression, and generalized additive models were used to produce predictive curves. Adjusted odds ratios (AOR) were controlled for high-risk age intervals (<20, >35).

Results: Records of 14,996 women were available for analysis (n= 8,879 pre-intervention and 6,087 post-intervention). Demographic characteristics between the two groups were similar. Significant improvements in MM (1,104/100,000 [1.10%] vs 279/100,000 [0.28%], P<.001) and PPH (14.01% vs 4.90%, P<.001) were observed pre- vs post-intervention. Infant mortality also improved (3.44% vs 2.58%, P=.004) but was still high. Laboratory evaluations (only drawn when deemed “in distress” due to resource limitation) on admission were available for ≈13% of women (n=1,954) and revealed that anemia or thrombocytopenia were strongly associated with PPH, in the pre- as well as the post-intervention period. Despite the sharp decline in post-intervention PPH, moderate and severe anemia (hemoglobin <10 g/dL) remained a strong PPH risk factor (AOR=3.31, P<.001). The same was true for thrombocytopenia (platelets <150 x109/L) (AOR=4.55, P<.001). The risk of PPH increased with increasing anemia severity and was additive in the presence of thrombocytopenia. Cryoprecipitate and Tranexamic acid were used to intervene in 39.26% (n=117) and 16.11% (n=48) of post-intervention PPH cases, respectively. Across both phases: eclampsia (AOR=3.49, P<.001), parity >4 (AOR=2.50, P<.001), pre-term delivery (AOR=2.00, P<.001), maternal age <20 (OR=1.73, P=.005), maternal age >35 (OR=1.73, P=.001), and pre-eclampsia (AOR=1.66, P<.001) were some of the predominant risk factors associated with PPH. Uterine atony, although rare (147 cases, ≈1%), invariably preceded PPH (135/147, 91.84%). Assessing residency impact, “non-local” women (living outside Maputo, ≈50%) and local women revealed improvements in MM and PPH. However, in general, non-local women tended to have more prevalent risk factors and worse outcomes than local women. In contrast, PPH incidence (≈10%), rates of anemia (≈50%), thrombocytopenia (≈20%), and distributions of hemoglobin and platelets were similar. Also, the strong association of PPH with anemia and/or thrombocytopenia was present pre- and post-intervention for both groups.

Conclusions: MM and PPH were extremely high during the pre-intervention phase and associated with correctable risk factors (including pre-natal anemia). The substantial reduction of MM and PPH following a dedicated effort to institute a multi-faceted PPH prevention and intervention program demonstrates the effectiveness of those measures as a future guide across the region. Addressing management of prenatal anemia, which facilitates PPH, may be additional steps to improve MM.

Disclosures: von Drygalski: Biomarin: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Pfizer: Consultancy, Research Funding; Bioverativ/Sanofi: Consultancy, Research Funding; CSL-Behring: Consultancy, Honoraria; Novo Nordisk: Consultancy, Honoraria; Sparx Therapeutics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Hematherix LLC: Other: Co-founder.

*signifies non-member of ASH